Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia

Ayalew Tefferi, Brian Jack Bartholmai, Thomas Elmer Witzig, Robert Brian Jenkins, Chin Yang Li, Curtis A. Hanson, Ruben A. Mesa, Robert L. Phyliky

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

In a prospective study of 93 consecutive untreated patients with B-cell chronic lymphocytic leukemia, we examined the clinical relevance of surface immunoglobulin (sIg) heavy chain (HC) and light chain (LC) isotypes. CD11c or CD25 expression, and the presence of trisomy 12 by fluorescence in situ hybridization (FISH). Careful morphologic evaluation was performed to exclude patients with other forms of chronic lymphoid leukemias, including mantle cell lymphoma, prolymphocytic leukemia, and leukemic phase of lymphoma. In addition, clonally restricted sIg and CD5 surface determinant were expressed in all patients. Clinical presentation, including blood cell counts, clinical stage, and organomegaly, did not correlate with any of the measured variables. After a median follow-up period of 3 years, the particular HC or LC isotype or CD11c expression did not correlate with either disease progression of treatment-free survival. However, trisomy 12 CD25 expressions were both associated with accelerated disease progression and a shorter treatment-free survival time. Our results confirm the adverse prognostic significance of trisomy 12 expression in chronic lymphocytic leukemia and suggest that CD25 expression may have an unfavorable clinical impact.

Original languageEnglish (US)
Pages (from-to)173-177
Number of pages5
JournalCancer Genetics and Cytogenetics
Volume95
Issue number2
DOIs
StatePublished - Jun 1997

Fingerprint

Trisomy
B-Cell Chronic Lymphocytic Leukemia
B-Cell Antigen Receptors
Disease Progression
Prolymphocytic Leukemia
Lymphoid Leukemia
Mantle-Cell Lymphoma
Light
Immunoglobulin Heavy Chains
Blood Cell Count
Fluorescence In Situ Hybridization
Disease-Free Survival
Lymphoma
Prospective Studies
Survival
Therapeutics

ASJC Scopus subject areas

  • Cancer Research
  • Genetics
  • Molecular Biology

Cite this

Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia. / Tefferi, Ayalew; Bartholmai, Brian Jack; Witzig, Thomas Elmer; Jenkins, Robert Brian; Li, Chin Yang; Hanson, Curtis A.; Mesa, Ruben A.; Phyliky, Robert L.

In: Cancer Genetics and Cytogenetics, Vol. 95, No. 2, 06.1997, p. 173-177.

Research output: Contribution to journalArticle

@article{d36980915cce4ca0af66c07c6986543d,
title = "Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia",
abstract = "In a prospective study of 93 consecutive untreated patients with B-cell chronic lymphocytic leukemia, we examined the clinical relevance of surface immunoglobulin (sIg) heavy chain (HC) and light chain (LC) isotypes. CD11c or CD25 expression, and the presence of trisomy 12 by fluorescence in situ hybridization (FISH). Careful morphologic evaluation was performed to exclude patients with other forms of chronic lymphoid leukemias, including mantle cell lymphoma, prolymphocytic leukemia, and leukemic phase of lymphoma. In addition, clonally restricted sIg and CD5 surface determinant were expressed in all patients. Clinical presentation, including blood cell counts, clinical stage, and organomegaly, did not correlate with any of the measured variables. After a median follow-up period of 3 years, the particular HC or LC isotype or CD11c expression did not correlate with either disease progression of treatment-free survival. However, trisomy 12 CD25 expressions were both associated with accelerated disease progression and a shorter treatment-free survival time. Our results confirm the adverse prognostic significance of trisomy 12 expression in chronic lymphocytic leukemia and suggest that CD25 expression may have an unfavorable clinical impact.",
author = "Ayalew Tefferi and Bartholmai, {Brian Jack} and Witzig, {Thomas Elmer} and Jenkins, {Robert Brian} and Li, {Chin Yang} and Hanson, {Curtis A.} and Mesa, {Ruben A.} and Phyliky, {Robert L.}",
year = "1997",
month = "6",
doi = "10.1016/S0165-4608(96)00249-X",
language = "English (US)",
volume = "95",
pages = "173--177",
journal = "Cancer Genetics and Cytogenetics",
issn = "0165-4608",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Clinical correlations of immunophenotypic variations and the presence of trisomy 12 in B-cell chronic lymphocytic leukemia

AU - Tefferi, Ayalew

AU - Bartholmai, Brian Jack

AU - Witzig, Thomas Elmer

AU - Jenkins, Robert Brian

AU - Li, Chin Yang

AU - Hanson, Curtis A.

AU - Mesa, Ruben A.

AU - Phyliky, Robert L.

PY - 1997/6

Y1 - 1997/6

N2 - In a prospective study of 93 consecutive untreated patients with B-cell chronic lymphocytic leukemia, we examined the clinical relevance of surface immunoglobulin (sIg) heavy chain (HC) and light chain (LC) isotypes. CD11c or CD25 expression, and the presence of trisomy 12 by fluorescence in situ hybridization (FISH). Careful morphologic evaluation was performed to exclude patients with other forms of chronic lymphoid leukemias, including mantle cell lymphoma, prolymphocytic leukemia, and leukemic phase of lymphoma. In addition, clonally restricted sIg and CD5 surface determinant were expressed in all patients. Clinical presentation, including blood cell counts, clinical stage, and organomegaly, did not correlate with any of the measured variables. After a median follow-up period of 3 years, the particular HC or LC isotype or CD11c expression did not correlate with either disease progression of treatment-free survival. However, trisomy 12 CD25 expressions were both associated with accelerated disease progression and a shorter treatment-free survival time. Our results confirm the adverse prognostic significance of trisomy 12 expression in chronic lymphocytic leukemia and suggest that CD25 expression may have an unfavorable clinical impact.

AB - In a prospective study of 93 consecutive untreated patients with B-cell chronic lymphocytic leukemia, we examined the clinical relevance of surface immunoglobulin (sIg) heavy chain (HC) and light chain (LC) isotypes. CD11c or CD25 expression, and the presence of trisomy 12 by fluorescence in situ hybridization (FISH). Careful morphologic evaluation was performed to exclude patients with other forms of chronic lymphoid leukemias, including mantle cell lymphoma, prolymphocytic leukemia, and leukemic phase of lymphoma. In addition, clonally restricted sIg and CD5 surface determinant were expressed in all patients. Clinical presentation, including blood cell counts, clinical stage, and organomegaly, did not correlate with any of the measured variables. After a median follow-up period of 3 years, the particular HC or LC isotype or CD11c expression did not correlate with either disease progression of treatment-free survival. However, trisomy 12 CD25 expressions were both associated with accelerated disease progression and a shorter treatment-free survival time. Our results confirm the adverse prognostic significance of trisomy 12 expression in chronic lymphocytic leukemia and suggest that CD25 expression may have an unfavorable clinical impact.

UR - http://www.scopus.com/inward/record.url?scp=0030928277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030928277&partnerID=8YFLogxK

U2 - 10.1016/S0165-4608(96)00249-X

DO - 10.1016/S0165-4608(96)00249-X

M3 - Article

C2 - 9169037

AN - SCOPUS:0030928277

VL - 95

SP - 173

EP - 177

JO - Cancer Genetics and Cytogenetics

JF - Cancer Genetics and Cytogenetics

SN - 0165-4608

IS - 2

ER -